A pregnant patient with ALK‑positive non‑small cell lung cancer treated with alectinib: A case report and review of the literature

De Smedt,Fabian; Dessy,Frédérique; Carestia,Luciano; Baldin,Pamela; Nana,Frank Aboubakar; Clapuyt,Philippe; Boon,Véronique; Amant,Frédéric; Gziri,Mina Mhallem

doi:10.3892/ol.2022.13640

A pregnant patient with ALK‑positive non‑small cell lung cancer treated with alectinib: A case report and review of the literature

Authors:
- Fabian De Smedt
- Frédérique Dessy
- Luciano Carestia
- Pamela Baldin
- Frank Aboubakar Nana
- Philippe Clapuyt
- Véronique Boon
- Frédéric Amant
- Mina Mhallem Gziri
View Affiliations

Affiliations: Department of Obstetrics, Clinique Saint‑Pierre, 1340 Ottignies, Belgium, Department of Obstetrics, Cliniques Universitaires Saint‑Luc, 1200 Brussels, Belgium, Department of Pneumology, Clinique Saint‑Pierre, Avenue Reine Fabiola 9, 1340 Ottignies, Belgium, Department of Pathology, Cliniques Universitaires Saint‑Luc, 1200 Brussels, Belgium, Department of Pneumology, Cliniques Universitaires Saint‑Luc, 1200 Brussels, Belgium, Department of Radiology, Cliniques Universitaires Saint‑Luc, 1200 Brussels, Belgium, Department of Gynecologic Oncology, UZ Leuven, Herestraat 49, 3000 Leuven, Belgium
Published online on: December 20, 2022 https://doi.org/10.3892/ol.2022.13640
Article Number: 54
Copyright: © De Smedt et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Oncogenic rearrangements in the anaplastic lymphoma kinase (ALK) gene account for 5% of non‑small cell lung cancer (NSCLC) cases. ALK inhibitors have markedly improved the outcome of metastatic ALK‑positive NSCLC (ALK⁺ mNSCLC) by increasing long‑term overall survival. Although a diagnosis of NSCLC during pregnancy or the peripartum period is rare, ALK⁺ NSCLC accounts for 38% of NSCLC cases in women of childbearing age (18‑45 years old). The younger age and prolonged survival of patients with ALK⁺ mNSCLC bring new challenges for lung cancer and obstetrics research, and raises questions related to pregnancy and family planning. The present study described normal fetal development and no obstetric complications in a patient infected with HIV diagnosed with ALK⁺ mNSCLC, who became pregnant during treatment with alectinib, a third‑generation ALK inhibitor.

View Figures

View References

1	Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A and Bray F: Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 71:209–249. 2021. View Article : Google Scholar : PubMed/NCBI
2	Recondo G, Facchinetti F, Olaussen KA, Besse B and Friboulet L: Making the first move in EGFR-driven or ALK-driven NSCLC: First-generation or next-generation TKI? Nat Rev Clin Oncol. 15:694–708. 2018. View Article : Google Scholar : PubMed/NCBI
3	Pacheco JM, Gao D, Smith D, Purcell T, Hancock M, Bunn P, Robin T, Liu A, Karam S, Gaspar L, et al: Natural History and Factors Associated with Overall Survival in Stage IV ALK-Rearranged Non-small cell lung cancer. J Thorac Oncol. 14:691–700. 2019. View Article : Google Scholar : PubMed/NCBI
4	Shokoohi A, Al-Hashami Z, Moore S, Pender A, Wong SK, Wang Y, Leung B, Wu J and Ho C: Effect of targeted therapy and immunotherapy on advanced nonsmall-cell lung cancer outcomes in the real world. Cancer Med. 11:86–93. 2022. View Article : Google Scholar : PubMed/NCBI
5	Cameron LB, Hitchen N, Chandran E, Morris T, Manser R, Solomon BJ and Jordan V: Targeted therapy for advanced anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung cancer. Cochrane Database Syst Rev. 1:CD0134532022.PubMed/NCBI
6	Bittner N, Ostoros G and Geczi L: New treatment options for lung adenocarcinoma-in view of molecular background. Pathol Oncol Res. 20:11–25. 2014. View Article : Google Scholar : PubMed/NCBI
7	Nishio M, Nakagawa K, Mitsudomi T, Yamamoto N, Tanaka T, Kuriki H, Zeaiter A and Tamura T: Analysis of central nervous system efficacy in the J-ALEX study of alectinib versus crizotinib in ALK-positive non-small-cell lung cancer. Lung Cancer. 121:37–40. 2018. View Article : Google Scholar : PubMed/NCBI
8	Larkins E, Blumenthal GM, Chen H, He K, Agarwal R, Gieser G, Stephens O, Zahalka E, Ringgold K, Helms W, et al: FDA approval: Alectinib for the treatment of metastatic, ALK-positive non-small cell lung cancer following crizotinib. Clin Cancer Res. 22:5171–5176. 2016. View Article : Google Scholar : PubMed/NCBI
9	Paik J and Dhillon S: Alectinib: A review in advanced, ALK-Positive NSCLC. Drugs. 78:1247–1257. 2018. View Article : Google Scholar : PubMed/NCBI
10	Dagogo-Jack I, Gainor JF, Porter RL, Schultz KR, Solomon BJ, Stevens S, Azzoli CG, Sequist LV, Lennes IT and Shaw AT: Clinicopathologic features of NSCLC diagnosed during pregnancy or the peripartum period in the era of molecular genotyping. J Thorac Oncol. 11:1522–1528. 2016. View Article : Google Scholar : PubMed/NCBI
11	Boussios S, Han SN, Fruscio R, Halaska MJ, Ottevanger PB, Peccatori FA, Koubková L, Pavlidis N and Amant F: Lung cancer in pregnancy: Report of nine cases from an international collaborative study. Lung Cancer. 82:499–505. 2013. View Article : Google Scholar : PubMed/NCBI
12	Pavlidis N: Lung cancer during pregnancy: An emerging issue. Lung Cancer. 59:279–281. 2008. View Article : Google Scholar : PubMed/NCBI
13	Van Calsteren K, Heyns L, De Smet F, Van Eycken L, Gziri MM, Van Gemert W, Halaska M, Vergote I, Ottevanger N and Amant F: Cancer during pregnancy: An analysis of 215 patients emphasizing the obstetrical and the neonatal outcomes. J Clin Oncol. 28:683–689. 2010. View Article : Google Scholar : PubMed/NCBI
14	Moran BJ, Yano H, Al Zahir N and Farquharson M: Conflicting priorities in surgical intervention for cancer in pregnancy. Lancet Oncol. 8:536–544. 2007. View Article : Google Scholar : PubMed/NCBI
15	Cardonick E and Iacobucci A: Use of chemotherapy during human pregnancy. Lancet Oncol. 5:283–291. 2004. View Article : Google Scholar : PubMed/NCBI
16	Amant F, Van Calsteren K, Halaska MJ, Gziri MM, Hui W, Lagae L, Willemsen MA, Kapusta L, Van Calster B, Wouters H, et al: Long-term cognitive and cardiac outcomes after prenatal exposure to chemotherapy in children aged 18 months or older: An observational study. Lancet Oncol. 13:256–264. 2012. View Article : Google Scholar : PubMed/NCBI
17	de Haan J, Verheecke M, Van Calsteren K, Van Calster B, Shmakov RG, Mhallem Gziri M, Halaska MJ, Fruscio R, Lok CAR, Boere IA, et al: Oncological management and obstetric and neonatal outcomes for women diagnosed with cancer during pregnancy: A 20-year international cohort study of 1170 patients. Lancet Oncol. 19:337–346. 2018. View Article : Google Scholar : PubMed/NCBI
18	Stovall M, Blackwell CR, Cundiff J, Novack DH, Palta JR, Wagner LK, Webster EW and Shalek RJ: Fetal dose from radiotherapy with photon beams: Report of AAPM Radiation Therapy Committee Task Group No. 36. Med Phys. 22:63–82. 1995. View Article : Google Scholar : PubMed/NCBI
19	Borgers JSW, Heimovaara JH, Cardonick E, Dierickx D, Lambertini M, Haanen JBAG and Amant F: Immunotherapy for cancer treatment during pregnancy. Lancet Oncol. 22:e550–e561. 2021. View Article : Google Scholar : PubMed/NCBI
20	Amant F, Han SN, Gziri MM, Vandenbroucke T, Verheecke M and Van Calsteren K: Management of cancer in pregnancy. Best Pract Res Clin Obstet Gynaecol. 29:741–753. 2015. View Article : Google Scholar : PubMed/NCBI
21	Acosta Rojas A, Collazo-Lorduy A, Remon J, Hernando Requejo O, Jiménez-Munarriz B, Rubio Rodríguez MC and De Castro J: Lung Adenocarcinoma during Pregnancy: 11-Year Follow-Up. Case Rep Oncol. 13:892–895. 2020. View Article : Google Scholar : PubMed/NCBI
22	Komura M, Yagishita S, Nakamura K, Arano N, Takeshige T, Muraki K, Nagashima O, Izumi H, Tomita S, Sasaki S and Takahashi K: A case of a pregnant woman diagnosed as having ALK-rearranged lung adenocarcinoma. In Vivo. 32:1205–1209. 2018. View Article : Google Scholar : PubMed/NCBI
23	Neves I, Mota PC and Hespanhol VP: Lung cancer during pregnancy: An unusual case. Rev Port Pneumol. 20:46–49. 2014.(In English, Portuguese). View Article : Google Scholar : PubMed/NCBI
24	Sariman N, Levent E, Yener NA, Orki A and Saygi A: Lung cancer and pregnancy. Lung Cancer. 79:321–323. 2013. View Article : Google Scholar : PubMed/NCBI
25	Peccatori FA, Azim HA Jr, Orecchia R, Hoekstra HJ, Pavlidis N, Kesic V and Pentheroudakis G; ESMO Guidelines Working Group, : Cancer, pregnancy and fertility: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 24 (Suppl 6):vi160–vi170. 2013. View Article : Google Scholar : PubMed/NCBI
26	Webb TR, Slavish J, George RE, Look AT, Xue L, Jiang Q, Cui X, Rentrop WB and Morris SW: Anaplastic lymphoma kinase: Role in cancer pathogenesis and small-molecule inhibitor development for therapy. Expert Rev Anticancer Ther. 9:331–356. 2009. View Article : Google Scholar : PubMed/NCBI
27	Scarfone G, Fumagalli M, Imbimbo M, Ceruti T, Cribiù FM, Di Loreto E, D'Incalci M, Facchin F, Fontana C, Garassino MC, et al: First case report of pregnancy on alectinib in a woman with metastatic ALK-Rearranged lung cancer: A case report. J Thorac Oncol. 16:873–877. 2021. View Article : Google Scholar : PubMed/NCBI